

UNITED STATES BANKRUPTCY COURT
DISTRICT OF NEW JERSEY
Caption in Compliance with D.N.J. LBR 9004-1

LOWENSTEIN SANDLER LLP

Jeffrey D. Prol, Esq.

John D. Hogoboom, Esq.

One Lowenstein Drive

Roseland, NJ 07068

Telephone: (973) 597-2500

Facsimile: (973) 597-2400

E-mail: jprol@lowenstein.com

E-mail: jhogoboom@lowenstein.com

*Special Counsel to the Debtors and
Debtors-In-Possession*

In re:

Immune Pharmaceuticals, Inc., *et al.*,¹

Debtors.

Chapter 11

Case No. 19-13273 (VFP)

(Jointly administered)

**ORDER ALLOWING FINAL APPLICATION OF LOWENSTEIN SANDLER LLP AS
SPECIAL COUNSEL TO THE DEBTORS AND DEBTORS-IN-POSSESSION FOR
SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD
FROM FEBRUARY 17, 2019 THROUGH APRIL 2, 2020**

The relief set forth on the following page, numbered two (2) through three (3), is
hereby **ORDERED**.

¹ The Debtors in these chapter 11 cases and the last four digits of each Debtor's taxpayer identification number are as follows: Immune Pharmaceuticals, Inc. (1431); Immune Pharmaceuticals, Ltd.; Cytovia, Inc. (7805); Immune Oncology Pharmaceuticals, Inc.; Maxim Pharmaceuticals, Inc. (9983); and Immune Pharmaceuticals USA Corp.(9630).

Page: 2

Debtors: Immune Pharmaceuticals, Inc., *et al.*

Case No.: 19-13273 (VFP)

Caption: *Order Allowing Final Application Of Lowenstein Sandler LLP As Special Counsel To The Debtors and Debtors-In-Possession For Services Rendered And Reimbursement of Expenses For The Period From February 17, 2019 Through April 2, 2020*

Upon the *Final Application Of Lowenstein Sandler LLP As Special Counsel To The Debtors and Debtors-In-Possession For Services Rendered And Reimbursement of Expenses For The Period From February 17, 2019 Through April 2, 2020* (the “Application”);² and due and proper notice of the Application having been given; and it appearing that no other or further notice is required; and it appearing that the Court has jurisdiction to consider the Application in accordance with 28 U.S.C. §§ 157 and 1334 and the *Standing Order of Reference to the Bankruptcy Court Under Title 11*, dated September 18, 2012 (Simandle, C.J.); and it appearing that venue is proper pursuant to 28 U.S.C. §§ 1408 and 1409; and it appearing that this is a core proceeding pursuant to 28 U.S.C. § 157(b)(2); and it appearing that the fees and expenses requested in the Application are reasonable and for necessary services provided to the Committee,

IT IS HEREBY ORDERED THAT:

1. The Application is granted as provided herein.
2. Lowenstein Sandler LLP is hereby allowed a final allowance of compensation for services rendered to the Committee in the sum of \$137,271.50 and reimbursement for costs incurred in the sum of \$6,043.42 for the period from February 17, 2019 through April 2, 2020.
3. The Debtors and/or the Chapter 7 Trustee are authorized and directed to make payment of the outstanding amount of such sums allowed pursuant to paragraph 3 above to Lowenstein Sandler LLP within fourteen (14) days of the entry of this Order.

² Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Application.

Page: 3

Debtors: Immune Pharmaceuticals, Inc., *et al.*

Case No.: 19-13273 (VFP)

Caption: *Order Allowing Final Application Of Lowenstein Sandler LLP As Special Counsel To
The Debtors and Debtors-In-Possession For Services Rendered And Reimbursement
of Expenses For The Period From February 17, 2019 Through April 2, 2020*

4. This Court shall retain jurisdiction over any and all matters arising from or related to the interpretation and/or implementation of this Order.